Novo Nordisk's inflammation drug fails to reduce cardiovascular risk in trial

NVO•2026-07-31

Trial misses cardiovascular endpoint

Novo Nordisk said on Friday its experimental drug failed to reduce the risk of major cardiovascular events in a late-stage trial involving patients with cardiovascular disease, chronic kidney disease and inflammation.

Novo Nordisk's inflammation drug fails to reduce cardiovascular risk in trial

Trial misses cardiovascular endpoint

Related News

RTX's Pratt & Whitney wins nearly $1.3 billion F135 engine spares contract

Diamondback Energy Inc <FANG.O>: Raymond James cuts target price to $248 from $249

AbbVie falls after trimming 2026 profit forecast

Peraso to report Q2 2026 results after market close, host conference call

BorgWarner appoints Rajesh Kalathur to board of directors